1000000 Stock Overview
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Eagle Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.80 |
| 52 Week High | US$27.00 |
| 52 Week Low | US$3.80 |
| Beta | 0.41 |
| 1 Month Change | -15.93% |
| 3 Month Change | -23.69% |
| 1 Year Change | -85.16% |
| 3 Year Change | -89.02% |
| 5 Year Change | -91.66% |
| Change since IPO | -62.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1000000 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -10.4% | 0.8% | 1.2% |
| 1Y | -85.2% | -24.4% | 2.0% |
Return vs Industry: 1E6 underperformed the German Biotechs industry which returned -24.4% over the past year.
Return vs Market: 1E6 underperformed the German Market which returned 2% over the past year.
Price Volatility
| 1000000 volatility | |
|---|---|
| 1000000 Average Weekly Movement | 13.5% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 1E6's share price has been volatile over the past 3 months.
Volatility Over Time: 1E6's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 134 | Mike Graves | www.eagleus.com |
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock.
Eagle Pharmaceuticals, Inc. Fundamentals Summary
| 1000000 fundamental statistics | |
|---|---|
| Market cap | €50.39m |
| Earnings (TTM) | €11.14m |
| Revenue (TTM) | €240.22m |
4.5x
P/E Ratio0.2x
P/S RatioIs 1000000 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1000000 income statement (TTM) | |
|---|---|
| Revenue | US$257.55m |
| Cost of Revenue | US$77.68m |
| Gross Profit | US$179.88m |
| Other Expenses | US$167.93m |
| Earnings | US$11.95m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.92 |
| Gross Margin | 69.84% |
| Net Profit Margin | 4.64% |
| Debt/Equity Ratio | 27.8% |
How did 1000000 perform over the long term?
See historical performance and comparison